ReposiTrak 과거 순이익 실적
과거 기준 점검 3/6
ReposiTrak은 연평균 17%의 비율로 수입이 증가해 온 반면, Software 산업은 수입이 22.5% 증가했습니다. 매출은 연평균 3.5%의 비율로 증가했습니다. ReposiTrak의 자기자본이익률은 14.4%이고 순이익률은 30.1%입니다.
핵심 정보
17.05%
순이익 성장률
18.34%
주당순이익(EPS) 성장률
| Software 산업 성장률 | 17.33% |
| 매출 성장률 | 3.50% |
| 자기자본이익률 | 14.43% |
| 순이익률 | 30.15% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • May 05
TRAK: Expanding Food Traceability Adoption And Compliance Wins Will Drive Upside
Analysts have kept their ReposiTrak price target effectively unchanged at approximately $16.00, reflecting only very small tweaks in inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the stock. What's in the News A wholesale grocery cooperative in the Southern United States became the first wholesaler to reach full supplier to store traceability using ReposiTrak’s Touchless Traceability solution, achieving FSMA 204 compliance without case-level scanning or changes to distribution center workflows (Key Developments).내러티브 업데이트 • Apr 19
TRAK: Expanding Traceability Network Adoption Will Support Future Upside
Analysts held ReposiTrak's fair value estimate at $16.00 per share while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the stock's risk and earnings profile. What's in the News ReposiTrak reported that eighteen fresh fruit and vegetable companies have joined the queue for the ReposiTrak Traceability Network to prepare for FDA Key Data Element sharing across their supply chains, covering a wide range of growers and distributors across the United States (Key Developments).내러티브 업데이트 • Apr 04
TRAK: Expanding Traceability Adoption And Share Repurchases Will Support Future Upside
Analysts have maintained their $16.00 price target on ReposiTrak, linking this steady view to only slight adjustments in discount rate and future P/E assumptions rather than any change in projected growth or profitability. What's in the News ReposiTrak and SPAR Group, Inc.내러티브 업데이트 • Mar 21
TRAK: Expanding Traceability Adoption And Share Repurchases Will Support Future Upside
Analysts have reaffirmed a $16.00 price target for ReposiTrak, citing only minimal tweaks to underlying assumptions such as discount rate, revenue growth, profit margin and future P/E, which together leave their overall valuation view effectively unchanged. What's in the News A grocery retailer using ReposiTrak Touchless Traceability is reported as the first to achieve end to end traceability under FDA FSMA Section 204, with hundreds of thousands of Key Data Element records generated across shipments, and several more corporate customers nearing similar go live milestones (Key Developments).내러티브 업데이트 • Mar 06
TRAK: Expanding Traceability Network And Share Buybacks Will Support Future Upside
Analysts have modestly reduced their price target on ReposiTrak to reflect a slightly lower future P/E assumption of 36.44x, while keeping key fair value and growth inputs broadly unchanged. What's in the News A grocery retailer using ReposiTrak Touchless Traceability has achieved end to end FSMA 204 traceability, generating hundreds of thousands of FDA Key Data Element records without case level scanning, with three more corporate customers close to similar go live points (Key Developments).내러티브 업데이트 • Feb 19
TRAK: Traceability Network Adoption Will Support Higher Future Profitability
Analysts have reduced their price target on ReposiTrak from $29 to $16, citing updated assumptions in their models for slower revenue growth, a lower future P/E multiple, and a higher profit margin profile. What's in the News ReposiTrak reported completing a share repurchase program announced on May 9, 2019, buying back a total of 2,220,026 shares, or 11.63% of the company, for US$14.46 million, including 79,927 shares, or 0.44%, repurchased between October 1, 2025 and December 31, 2025 for US$1.1 million (Key Developments).Seeking Alpha • Jan 13
ReposiTrak: Better Business, Fairer Price, Still Not A Buy
Summary ReposiTrak, Inc. is a micro-cap SaaS firm focused on supply chain compliance, food safety, and traceability for retailers and suppliers. TRAK's revenue grew 10% YoY, driven by recurring subscriptions and expanding services to existing customers, especially as retailer requirements outpace federal mandates. Operating expenses rose 3%, but revenue outpaced costs, supporting a 28% increase in operating income and strong revenue-per-employee metrics. Liquidity remains robust with $28.8M in cash and zero debt, though higher tax rates and rising costs warrant close monitoring if adoption slows. Read the full article on Seeking Alpha분석 기사 • Oct 01
Investors Will Want ReposiTrak's (NYSE:TRAK) Growth In ROCE To Persist
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...분석 기사 • Aug 02
Subdued Growth No Barrier To ReposiTrak, Inc.'s (NYSE:TRAK) Price
ReposiTrak, Inc.'s ( NYSE:TRAK ) price-to-earnings (or "P/E") ratio of 46.4x might make it look like a strong sell...분석 기사 • May 27
ReposiTrak's (NYSE:TRAK) Performance Is Even Better Than Its Earnings Suggest
ReposiTrak, Inc. ( NYSE:TRAK ) just reported healthy earnings but the stock price didn't move much. Investors are...분석 기사 • Apr 12
Earnings Not Telling The Story For ReposiTrak, Inc. (NYSE:TRAK)
With a price-to-earnings (or "P/E") ratio of 62.3x ReposiTrak, Inc. ( NYSE:TRAK ) may be sending very bearish signals...분석 기사 • Nov 09
ReposiTrak, Inc. (NYSE:TRAK) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 71.3x ReposiTrak, Inc. ( NYSE:TRAK ) may be sending very bearish signals...
새로운 내러티브 • Oct 07
Critical Focus On Traceability Solutions Powers Revenue Growth And Profitability Surge
Emphasis on enhancing traceability solutions and strategic revenue focus predicts significant growth, with aims to improve net margins and year-over-year growth.Seeking Alpha • Oct 06
Track And Trace, But Don't Race: Why ReposiTrak Might Be Overvalued
Summary ReposiTrak shows solid growth potential with traceability services and recurring revenue but is currently overvalued with a high P/E ratio of 62.09x. Despite strong financials and profitability, rising operational expenses and heavy FDA dependency pose significant risks. Expansion into adjacent markets and AI-driven operational efficiencies are promising, but traceability revenue remains a small portion of the business. Given the speculative nature and high valuation, I recommend holding off on investing in ReposiTrak at this price. Read the full article on Seeking Alpha분석 기사 • Jul 24
ReposiTrak, Inc.'s (NYSE:TRAK) P/E Is Still On The Mark Following 28% Share Price Bounce
ReposiTrak, Inc. ( NYSE:TRAK ) shareholders have had their patience rewarded with a 28% share price jump in the last...분석 기사 • Mar 23
ReposiTrak (NYSE:TRAK) Has More To Do To Multiply In Value Going Forward
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...분석 기사 • Feb 28
Why Investors Shouldn't Be Surprised By ReposiTrak, Inc.'s (NYSE:TRAK) 28% Share Price Surge
Despite an already strong run, ReposiTrak, Inc. ( NYSE:TRAK ) shares have been powering on, with a gain of 28% in the...매출 및 비용 세부 내역
매출 및 비용 세부 내역
ReposiTrak가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 23 | 7 | 12 | 0 |
| 31 Dec 25 | 24 | 7 | 12 | 0 |
| 30 Sep 25 | 23 | 7 | 12 | 0 |
| 30 Jun 25 | 23 | 7 | 11 | 0 |
| 31 Mar 25 | 22 | 6 | 11 | 0 |
| 31 Dec 24 | 21 | 6 | 11 | 0 |
| 30 Sep 24 | 21 | 6 | 11 | 0 |
| 30 Jun 24 | 20 | 5 | 11 | 0 |
| 31 Mar 24 | 20 | 5 | 11 | 0 |
| 31 Dec 23 | 20 | 5 | 10 | 0 |
| 30 Sep 23 | 19 | 5 | 10 | 0 |
| 30 Jun 23 | 19 | 5 | 10 | 0 |
| 31 Mar 23 | 19 | 5 | 10 | 0 |
| 31 Dec 22 | 19 | 4 | 10 | 0 |
| 30 Sep 22 | 18 | 4 | 10 | 0 |
| 30 Jun 22 | 18 | 3 | 10 | 0 |
| 31 Mar 22 | 18 | 3 | 10 | 0 |
| 31 Dec 21 | 20 | 3 | 10 | 0 |
| 30 Sep 21 | 20 | 4 | 10 | 0 |
| 30 Jun 21 | 21 | 4 | 10 | 0 |
| 31 Mar 21 | 22 | 3 | 10 | 0 |
| 31 Dec 20 | 21 | 2 | 10 | 0 |
| 30 Sep 20 | 20 | 1 | 10 | 0 |
| 30 Jun 20 | 20 | 1 | 11 | 0 |
| 31 Mar 20 | 19 | 1 | 11 | 0 |
| 31 Dec 19 | 19 | 2 | 10 | 0 |
| 30 Sep 19 | 20 | 3 | 10 | 0 |
| 30 Jun 19 | 21 | 3 | 11 | 0 |
| 31 Mar 19 | 23 | 4 | 11 | 0 |
| 31 Dec 18 | 23 | 4 | 11 | 0 |
| 30 Sep 18 | 23 | 3 | 12 | 0 |
| 30 Jun 18 | 22 | 3 | 11 | 0 |
| 31 Mar 18 | 21 | 2 | 11 | 0 |
| 31 Dec 17 | 20 | 3 | 10 | 0 |
| 30 Sep 17 | 19 | 3 | 10 | 0 |
| 30 Jun 17 | 19 | 3 | 9 | 0 |
| 31 Mar 17 | 18 | 3 | 9 | 0 |
| 31 Dec 16 | 16 | 2 | 8 | 0 |
| 30 Sep 16 | 15 | 1 | 9 | 0 |
| 30 Jun 16 | 14 | 0 | 9 | 0 |
| 31 Mar 16 | 14 | -3 | 9 | 0 |
| 31 Dec 15 | 13 | -6 | 10 | 0 |
| 30 Sep 15 | 13 | -7 | 10 | 0 |
| 30 Jun 15 | 14 | -7 | 10 | 0 |
양질의 수익: TRAK는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: TRAK의 현재 순 이익률 (30.1%)은 지난해 (28.8%)보다 높습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: TRAK의 수익은 지난 5년 동안 연평균 17% 증가했습니다.
성장 가속화: 지난 1년간 TRAK 의 수익 증가율(11.5%)은 5년 평균(연간 17%)보다 낮습니다.
수익 대 산업: TRAK의 지난 1년 수익 증가율(11.5%)은 Software 업계 평균(11.7%)을 능가하지 못했습니다.
자기자본이익률
높은 ROE: TRAK의 자본 수익률(14.4%)은 낮음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/27 02:24 |
| 종가 | 2026/05/27 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/06/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
ReposiTrak, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Thomas Forte | D.A. Davidson & Co. |
| Ananda Baruah | Loop Capital Markets |
| Thomas Forte | Maxim Group |